What is the role of dydrogesterone in pregnancy?

Role of Dydrogesterone in Pregnancy

Dydrogesterone is NOT recommended for prevention of preterm birth or miscarriage in pregnancy based on current evidence-based guidelines, which support only 17-alpha hydroxyprogesterone caproate (17OHP-C) for preterm birth prevention and show no benefit of progesterone for threatened miscarriage. 1, 2, 3

Evidence-Based Indications in Pregnancy

Preterm Birth Prevention: NOT Indicated

• For women with a prior spontaneous preterm birth, the guideline-endorsed first-line therapy is intramuscular 17OHP-C 250 mg weekly from 16–20 weeks until 36 weeks gestation—NOT dydrogesterone or any oral progesterone formulation. 1, 2

• The landmark 2003 Meis trial demonstrated a 34% reduction in recurrent preterm birth with 17OHP-C (from 54.9% to 36.3%), along with significant reductions in neonatal complications including intraventricular hemorrhage and necrotizing enterocolitis. 1

• Oral progesterone formulations, including dydrogesterone, have NO evidence supporting efficacy for preterm birth prevention and cannot replace 17OHP-C. 2

Short Cervix Management: Vaginal Progesterone Only

• For singleton pregnancies with cervical length ≤20–25 mm detected before 24 weeks (without prior preterm birth), vaginal micronized progesterone 90-mg gel or 200-mg suppository daily is recommended—NOT oral dydrogesterone. 2

• This regimen reduces preterm birth <33 weeks (RR 0.54) and composite neonatal morbidity/mortality (RR 0.41). 2

Threatened or Recurrent Miscarriage: NOT Recommended

• Current evidence shows NO benefit of progesterone supplementation—including dydrogesterone—for threatened miscarriage or symptomatic first-trimester bleeding. 3

• While older research studies suggest dydrogesterone may improve pregnancy outcomes in threatened or recurrent miscarriage 4, 5, these findings have not been incorporated into current evidence-based guidelines from the American College of Obstetricians and Gynecologists. 2, 3

• For women with early pregnancy bleeding, even those with prior miscarriage(s), vaginal micronized progesterone 400 mg twice daily may be considered as an alternative to 90-mg gel or 200-mg suppository daily, but dydrogesterone is not mentioned in guideline recommendations. 2

Situations Where NO Progesterone (Including Dydrogesterone) Is Effective

• Multiple gestations (twins, triplets): No benefit for preventing preterm birth, even with prior preterm delivery. 2

• Active preterm labor: Progesterone does not function as a tocolytic agent. 2

• Preterm premature rupture of membranes (PPROM): No therapeutic advantage. 2

• Routine pregnancy without risk factors: No demonstrated efficacy in singleton pregnancies without prior preterm birth and normal/unknown cervical length. 2

Emerging Safety Concerns

• A 2025 pharmacovigilance analysis from the WHO global safety database (VigiBase) identified a significantly increased reporting of birth defects with dydrogesterone exposure during early pregnancy, particularly hypospadias and congenital heart defects. 6

• The reporting odds ratio for birth defects with dydrogesterone was 5.4 (95% CI 3.9–7.5) compared to any other drug, and 5.4 (95% CI 3.7–7.9) compared specifically to progesterone. 6

• This possible safety signal emphasizes the need for caution and further investigation regarding the fetal safety profile of dydrogesterone. 6

Assisted Reproductive Technology Context

• Recent research suggests dydrogesterone may be effective for luteal phase support in IVF/ICSI cycles 7, 8, 9, 10, but this is a distinct indication from pregnancy maintenance and is not addressed in obstetric guidelines for spontaneous pregnancies. 2

Critical Clinical Pitfalls

• Do not confuse different progesterone formulations: Injectable 17OHP-C, oral micronized progesterone, vaginal progesterone, and dydrogesterone have different dosing, pharmacokinetics, and evidence bases—they are NOT interchangeable. 2

• Do not switch progesterone formulations based on cervical shortening: If cervical length shortens to ≤25 mm before 24 weeks in a woman already receiving 17OHP-C, add cerclage while continuing the same progesterone regimen; switching to dydrogesterone or vaginal progesterone is not evidence-based. 2

• Do not prescribe dydrogesterone at 6 weeks gestation for routine pregnancy support: There is insufficient evidence to recommend any progesterone in singleton gestations without prior preterm birth and unknown cervical length. 2

Summary of Guideline-Based Recommendations

Dydrogesterone has no established role in evidence-based obstetric guidelines for pregnancy maintenance, preterm birth prevention, or miscarriage prevention. Current guidelines support only specific formulations (17OHP-C intramuscularly or vaginal micronized progesterone) for narrowly defined high-risk populations, with emerging safety concerns about dydrogesterone warranting caution until further data are available. 1, 2, 3, 6